The DHRS3 antibody is a crucial tool in studying dehydrogenase/reductase 3 (DHRS3), a member of the short-chain dehydrogenase/reductase (SDR) superfamily. DHRS3. also known as retinol dehydrogenase 11 (RDH11), plays a role in retinoid metabolism by catalyzing the oxidation of retinol to retinaldehyde, a key step in synthesizing retinoic acid—a critical signaling molecule in cell differentiation and development. This enzyme is implicated in lipid metabolism, cellular homeostasis, and cancer progression, with studies linking its expression to tumor suppression in cancers like colon and breast cancer. Researchers utilize DHRS3 antibodies primarily for detecting and quantifying DHRS3 protein levels in immunoassays such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies are typically validated for specificity using knockout (KO) controls or siRNA-mediated knockdown to ensure minimal cross-reactivity with related SDR family members. Commercial DHRS3 antibodies are often produced in rabbits or mice, targeting specific epitopes within the protein's conserved regions. Recent studies have also explored DHRS3's role in metabolic disorders and its interaction with other retinoid-processing enzymes, underscoring the antibody's importance in both basic research and clinical applications. Proper validation and optimization of DHRS3 antibodies remain essential for reproducibility in studies investigating retinoid signaling pathways or DHRS3-associated diseases.